Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 4.59
(-2.34%)
CAD 4.59
(-2.34%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.78 Million CAD | 30.69% |
| 2022 | 10.54 Million CAD | 10.36% |
| 2021 | 9.55 Million CAD | -25.16% |
| 2020 | 12.76 Million CAD | 6.97% |
| 2019 | 11.93 Million CAD | 214.72% |
| 2018 | 3.79 Million CAD | 30306.97% |
| 2017 | 12.47 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 12.93 Million CAD | 23.75% |
| 2024 Q2 | 6.37 Million CAD | -63.97% |
| 2023 Q4 | 10.45 Million CAD | -32.2% |
| 2023 Q1 | 10.81 Million CAD | 2.59% |
| 2023 Q3 | 15.41 Million CAD | 38.45% |
| 2023 FY | 13.78 Million CAD | 30.69% |
| 2023 Q2 | 11.13 Million CAD | 2.91% |
| 2022 Q4 | 10.54 Million CAD | 2.48% |
| 2022 Q3 | 10.29 Million CAD | 2.67% |
| 2022 FY | 10.54 Million CAD | 10.36% |
| 2022 Q2 | 10.02 Million CAD | 2.54% |
| 2022 Q1 | 9.77 Million CAD | 2.28% |
| 2021 Q1 | 6.35 Million CAD | -50.23% |
| 2021 FY | 9.55 Million CAD | -25.16% |
| 2021 Q3 | 9.38 Million CAD | 6.11% |
| 2021 Q4 | 9.55 Million CAD | 1.87% |
| 2021 Q2 | 8.84 Million CAD | 39.1% |
| 2020 Q4 | 12.76 Million CAD | 1.04% |
| 2020 Q3 | 12.63 Million CAD | 0.0% |
| 2020 FY | 12.76 Million CAD | 6.97% |
| 2019 FY | 11.93 Million CAD | 214.72% |
| 2019 Q4 | 11.93 Million CAD | 0.0% |
| 2018 FY | 3.79 Million CAD | 30306.97% |
| 2017 FY | 12.47 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.18 Million CAD | -68.385% |
| Helix BioPharma Corp. | - CAD | -Infinity% |
| Microbix Biosystems Inc. | 6.64 Million CAD | -107.395% |
| Medicenna Therapeutics Corp. | - CAD | -Infinity% |
| Satellos Bioscience Inc. | - CAD | -Infinity% |
| Oncolytics Biotech Inc. | 423 Thousand CAD | -3158.166% |
| Sernova Corp. | 136.12 Thousand CAD | -10024.699% |